<DOC>
	<DOCNO>NCT02500043</DOCNO>
	<brief_summary>The purpose trial compare effect TAS-102 best supportive care ( BSC ) Placebo ( inactive drug ) best supportive care metastatic gastric cancer .</brief_summary>
	<brief_title>Study TAS-102 Placebo Plus BSC Patients With Metastatic Gastric Cancer</brief_title>
	<detailed_description>This multinational , double-blind , two-arm , parallel , randomized , Phase 3 study evaluate efficacy safety TAS-102 plus BSC versus placebo plus BSC patient metastatic gastric cancer previously receive least 2 prior regimen advance disease . Eligible patient centrally randomize ( 2:1 ) TAS-102 + BSC ( experimental arm ) placebo + BSC ( control arm ) .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Trifluridine</mesh_term>
	<criteria>1 . Has histologically confirm nonresectable , metastatic gastric adenocarcinoma include adenocarcinoma gastroesophageal junction . 2 . Has previously receive least 2 prior regimen advance disease refractory unable tolerate last prior therapy . 3 . Has measureable nonmeasurable disease define RECIST 1.1 criterion . 4 . Is able take medication orally ( ie , feed tube ) . 5 . Has ECOG performance status 0 1 . 6 . Has adequate organ function define protocol define lab . 7 . Women childbearing potential must negative pregnancy test must agree adequate birth control conception possible . Males must agree adequate birth control . 1 . Has certain serious illness medical condition 2 . Has certain recent treatment e.g . major surgery , anticancer therapy , extend field radiation , receive investigational agent within specified time frame prior study drug administration . 3 . Has previously receive TAS102 . 4 . Has unresolved toxicity great equal CTCAE Grade 2 attribute prior therapy . 5 . Is pregnant lactate female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Gastric Cancer</keyword>
	<keyword>Metastatic Gastric Cancer</keyword>
</DOC>